Literature DB >> 11577236

Trans-suppression of misfolding in an amyloid disease.

P Hammarström1, F Schneider, J W Kelly.   

Abstract

The transthyretin (TTR) amyloid diseases, representative of numerous misfolding disorders, are of considerable interest because there are mutations that cause or suppress disease. The Val30 --> Met30 (V30M) TTR mutation is the most prevalent cause of familial amyloid polyneuropathy in heterozygotes, whereas a Thr119 --> Met119 (T119M) mutation on the second TTR allele protects V30M carriers from disease. Here, we show that the incorporation of one or more T119M TTR subunits into a predominantly V30M tetramer strongly stabilized the mixed tetramer against dissociation. Dissociation is required for amyloid formation, so these findings provide a molecular explanation for intragenic trans-suppression of amyloidosis. The data also suggest a potential therapeutic strategy, provide insight into tissue-specific deposition and amyloid composition, and support the validity of the amyloid hypothesis in human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577236     DOI: 10.1126/science.1062245

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  86 in total

1.  Progress in transthyretin fibrillogenesis research strengthens the amyloid hypothesis.

Authors:  A Chakrabartty
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions.

Authors:  Arthur Horwich
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Exploring amyloid formation by a de novo design.

Authors:  Richard A Kammerer; Dirk Kostrewa; Jesús Zurdo; Andreas Detken; Carlos García-Echeverría; Janelle D Green; Shirley A Müller; Beat H Meier; Fritz K Winkler; Christopher M Dobson; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

4.  Discovery and characterization of a mammalian amyloid disaggregation activity.

Authors:  Amber N Murray; James P Solomon; Ya-Juan Wang; William E Balch; Jeffery W Kelly
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

5.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

6.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

7.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 8.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

9.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.